ASCO Annual Meeting

June 27, 2022

Results of a single-center study presented at the 2022 ASCO Annual Meeting showed that oral minoxidil may be effective in treating late alopecia. Moving forward, these efforts in survivorship care will need to be expanded to less resourced areas, experts said.

June 21, 2022

The intracranial objective response rate was 32% among patients with KRAS G12C–mutant, non–small cell lung cancer who received adagrasib.

June 21, 2022

Phase 2 findings found that patients with chemotherapy-induced anemia experienced increases in hemoglobin following treatment with roxadustat.

June 19, 2022

Daratumumab plus lenalidomide and dexamethasone bested standard therapy in producing rapid, deep, and durable responses across subgroups of patients with newly diagnosed multiple myeloma.

June 18, 2022

Phase 3 findings showed that panitumumab plus mFOLFOX significantly improved overall survival in patients with RAS wild-type metastatic colorectal cancer.

June 17, 2022

Regardless of other identified driver genomic alterations, patients with heavily pretreated, advanced, non–small cell lung cancer achieved encouraging responses with patritumab deruxtecan.

June 17, 2022

A study analyzing the long-term adrenal insufficiency outcomes of patients receiving immune checkpoint inhibition therapy found that secondary insufficiency was more common than primary in this patient population.

June 14, 2022

A real-world analysis showed that the proportion of women with ovarian cancer who required dose modifications or treatment discontinuations while receiving PARP inhibitors differed significantly between olaparib, niraparib, and rucaparib.

June 13, 2022

Patients with hormone receptor¬–positive, HER2-negative, node-positive high-risk early breast cancer who have certain characteristics may benefit from early dose adjustments with adjuvant abemaciclib.

June 12, 2022

Frontline nivolumab and ipilimumab combination therapy was associated with increased 5-year survivorship in patients with metastatic non–small cell lung cancer—regardless of PD-L1 expression.